Darapladib
- Catalog NO.:A822896
- CAS No. : 356057-34-6
- Molecular Formula:C36H38F4N4O2S
- Molecular Weight: 666.77
Note*
1. Please click the to confirm the discount and stock quantity.
2. Click“Bulk Inquiry”to ask for quotations of other quantity.
3. The price does not include shipping and bank charges.
Bulk Inquiry
1. Please click the to confirm the discount and stock quantity.
2. Click“Bulk Inquiry”to ask for quotations of other quantity.
3. The price does not include shipping and bank charges.
Product Details
CAS Number | 356057-34-6 | Appearance | White powder |
Catalog Number | A822896 | MDL Number | MFCD18251452 |
Molecular Formula | C36H38F4N4O2S | Molecular Weight | 666.77 |
Boiling Point | 741.002°C at 760 mmHg | Melting Point | |
Flash Point | Density | ||
Synonyms | SB 480848;N-[2-(diethylamino)ethyl]-2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-1H-Cyclopentapyrimidine-1-acetamide | ||
Storage Condition | Store in a tightly closed container,in a cool and dry place |
Safety
GHS Pictogram | |||
Signal Word | Warning | UN Number | |
Hazard Statements | H302-H315-H319-H335 | Class | |
Precautionary Statements | P261-P305+P351+P338 | Packing Group |
Description
Darapladib, also known as SB-480848, is a reversible lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor with IC50 of 0.25 nM, which is in Phase 3 trials. Recent studies showed that risk of major coronary events not reduced by darapladib therapy. In patients with stable coronary heart disease, darapladib did not significantly reduce the risk of the primary composite end point of cardiovascular death, myocardial infarction, or stroke. |